Neuropathic pain (NP) is an increasingly common chronic pain state and a major health burden, affecting approximately 7% to 10% of the general population. Emerging evidence suggests that genetic factors could partially explain individual susceptibility to NP and the estimated heritability in twins is 37%. The aim of this study was to systematically review and summarize the studies in humans that have investigated the influence of genetic factors associated with NP. We conducted a comprehensive literature search and performed meta-analyses of all the potential genetic variants associated with NP. We reviewed 29 full-text articles and identified 28 genes that were significantly associated with NP, mainly involved in neurotransmission, immune response, and metabolism. Genetic variants in HLA genes, COMT, OPRM1, TNFA, IL6, and GCH1, were found to have an association with NP in more than one study. In the meta-analysis, polymorphisms in HLA-DRB1*13 (odds ratio [OR], 2.96; confidence interval [CI], 1.93-4.56), HLA-DRB1*04 (OR, 1.40; CI, 1.02-1.93), HLA-DQB1*03 (OR, 2.86; CI, 1.57-5.21), HLA-A*33 (OR, 2.32; CI, 1.42-3.80), and HLA-B*44 (OR, 3.17; CI, 2.22-4.55) were associated with significantly increased risk of developing NP, whereas HLA-A*02 (OR, 0.64; CI, 0.47-0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; CI, 0.27-1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with NP. These findings demonstrate an important and specific contribution of genetic factors to the risk of developing NP. However, large-scale replication studies are required to validate these candidate genes. Our review also highlights the need for genome-wide association studies with consistent case definition to elucidate the genetic architecture underpinning NP.
Introduction
Neuropathic pain (NP) is an increasingly common chronic pain state, arising as a result of a lesion or disease affecting the somatosensory system. 50, 70 Neuropathic pain is a complex condition with distinct symptoms and has a great impact on health-related quality of life, sleep, mood, and anxiety. 16, 62 Neuropathic pain affects approximately 7% to 10% of the general population, 5, 28 20% to 26.4% of individuals with diabetes, 6, 12 and 10% to 20% of individuals after herpes zoster (HZ) in the United Kingdom. 25, 39, 78 Up to 37% of individuals with low back pain 23, 56 and 40% of people after surgery 38 suffer from NP. Studies have found that NP affects approximately 8.1% and 17.9% of the Canadian population. 69, 72 Inoue et al. 35 reported that the prevalence of NP is lower (3.2%) in the East Asian population.
Genetic susceptibility as well as environmental factors, such as sociodemographic, psychological, clinical, and lifestyle factors, are known to contribute to the risk of developing NP. 22, 27, 43 Evidence from human genetic studies have shown that some rare NP disorders including congenital sensitivity to pain with anhidrosis, erythromelalgia, and paroxysmal extreme pain disorder are monogenic, caused by mutations in a single gene, SCN9A. 15, 18, 34, 79 It has been proposed that the contribution of multiple genes can help to understand why some individuals are susceptible to chronic NP after nerve injury or disease while others are not. Initially, several animal model studies established that NP is partially heritable 13, 14 and show the existence of gene-environment interactions in NP susceptibility. Recently, a twins study from the UK reported an estimated heritability of NP of 37%, 52 suggesting that genetic factors have the potential to determine a significant proportion of an individual's predisposition to NP. A recent genome-wide associated study (GWAS) also found that NP had a heritable component (11%) in a diabetic population. 49 Several genetic association studies have found variants associated with the risk of developing NP in different conditions as well as affecting pain severity. However, the underlying genetic mechanisms contributing to NP remain elusive due to inconsistent results and lack of validation in the current evidence.
Identifying genetic factors for NP and summarising the results from all studies to date will help to confirm known potential genetic risk variants underlying NP, which may provide useful biomarkers for clinical prognosis and pharmacological targets. We therefore performed a comprehensive literature-based systematic review to
Data collection
The first author (A.V.) performed literature searches and removed the duplicates identified in all 5 databases. Articles were screened using the key words in titles and abstracts using R 67 script and verified manually to determine whether they met the above study criteria. Articles were examined and assessed independently by A.V. and the second author (H.L.H.). Furthermore, reference lists of all screened articles were used to retrieve additional studies by hand search. Subsequently, full-text articles were retrieved and reviewed for eligibility. Any disagreements were discussed between A.V. and H.L.H. The list of excluded studies after fulltext screening can be found in supplementary Table S3 (available online at http://links.lww.com/PAIN/A534). Twenty-seven articles were included from preliminary searches and then we re-ran the searches in April 2017 using the original search strategies to include any more recent studies.
Data extraction
Data extraction was performed by the first author and any clarification was discussed with last author (B.H.S.). The quality of all included studies was evaluated according to the Strengthening the Reporting of Genetic Association (STREGA) study guidelines. 45 The quality score was calculated for each study based on the 22 key items grouped into 7 categories: title and abstract, background, study selection, statistical methods, reporting outcome, statistical methods, previous supporting evidence or validation, and funding source information (see supplementary Tables S4, S5 ; available online at http://links.lww. com/PAIN/A534) and scores ranged from 0 (lowest) to 30 (highest). Higher scores represent studies of higher quality. The following information was extracted from all the included studies: first author, year, study type, study characteristics, genotype method, genes, genetic markers, allele frequencies, statistical model, and outcomes. Information on the transcriptional and epigenetic regulation of single nucleotide polymorphisms (SNPs) were obtained using the RegulomeDB, 7 UCSC genome browser, 63 and HaploReg. 76 
Meta-analysis
We conducted meta-analyses of all the potential risk variants that were reported by more than one study on different NP conditions. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using reported allele frequencies by authors. We performed fixed effect meta-analyses to determine the summary risk estimates and CIs, and assessed the heterogeneity across the studies by calculating I 2 , and heterogeneity P-value from Cochrane Q test and generated forest plots using metafor Rpackage. 74 Publication bias was assessed using Egger regression test for asymmetry and funnel plots were generated using metafor R-package. 74 
Results

Study selection
The systematic literature searches resulted in 3461 studies after removing duplicates and non-English language articles. We did not find any additional studies through other resources. After screening titles and abstracts, 48 relevant full-text articles were assessed, of which 21 articles that did not meet the study criteria were excluded because they were treatment response studies, studies investigating genetic predictors for NP severity, or studies investigating pain-related conditions that are not considered to be NP. Figure 1 illustrates the study selection process and reasons for full-text articles' exclusion. Two studies 9, 77 were identified when we updated the systematic search until April 2017. We therefore identified a total of 29 studies for inclusion in this review published between January 1999 and April 2017.
Characteristics of included studies
The characteristics of the study type, sample size, case-control ascertainment, and study population are summarized in Table 1 . Of the 29 studies, 21 were CGAS, 4 used traditional molecular genetic methods, and 3 used GWAS on different NP conditions. The most studied NP conditions were persistent postsurgical pain (PPSP), painful diabetic peripheral neuropathy (PDPN), postherpetic neuralgia (PHN), and sciatica. Other NP conditions, including carpal tunnel syndrome (CTS), trigeminal neuralgia (TN), and pain in multiple sclerosis (MS) patients were studied at least once (Fig. 2) . Seventeen studies investigated NP risk in a European population, 7 studies were based in an East Asian population, 2 studies were conducted in an American population with admixed ancestry, and other studies were conducted in Israeli and South African populations. Most of the studies had a very small sample size (,500 samples). Neuropathic pain case ascertainment varied across the studies: 24 studies screened the subjects based on clinical examination and/or used an assessment tool and questionnaires for pain (magnetic resonance imaging, quantitative sensory testing, and monofilament test), 2 studies used only questionnaires (Inguinal Pain and painDE-TECT), and 2 studies from the same cohort used a prescription history and/or clinical assessment tool. In all studies, either healthy subjects with no history of pain, or patients affected by disease of interest who did not develop NP were defined as controls. All included studies mainly focussed on the influence of genetic variants in the risk of developing NP and a very small number of studies examined the genetic factors for NP severity as well. Table 2 presents the summary of genetic markers, genotype method, and statistical modelling used in all 29 studies, study outcomes, risk alleles identified, information on Hardy-Weinberg equilibrium, effect sizes, CIs, and P-values, if they were provided by the authors. The calculated quality score for all genetic association studies is shown in Table 2 . The accuracy and transparency of reporting study outcomes improved from earlier studies to most recent studies (see supplementary Figure S1 , available online at http://links.lww.com/PAIN/A534).
Molecular genetics studies
Studies on molecular genetics identified an association between NP and variants in 3 genes (SCN9A, SCN11A, and MPZ) encoding voltage-gated sodium channel and myelin zero protein, respectively. Two studies 11, 26 reported an association between R1150W mutations in the SCN9A gene and chronic NP. Huang et al. 33 found 8 mutations in the SCN11A gene in 12 unrelated individuals from a cohort of 345 subjects with painful peripheral neuropathy. Ramirez et al. 57 reported an association between Trp101stop mutations (MPZ) in individuals affected with hereditary neuropathy and debilitating NP.
Genetic association studies
We identified genetic polymorphisms in or near 34 genes, of which 26 (from CGAS and GWAS) were significantly associated with NP in at least one study cohort. Eight genes that had previously been postulated as candidates, based on biological evidence, showed no statistical significance in their association with NP in our systematic review: matrix metallopeptidase 1 (MMP1); cytochrome P450 Family 2 Subfamily D Member 6 (CYP2D6); transient receptor potential cation channel subfamily A member 1 (TRPA1); transient receptor potential cation channel vanilloid subfamily member 1 (TRPV1); transient receptor potential cation channel subfamily M member 8 (TRPM8); brainderived neurotrophic factor (BDNF); calcium voltage-gated channel alpha2 delta 2 subunit (CACNAD2); and glutamate ionotropic receptor kainate type subunit 4 (GRIK2). Some studies reported genetic variants in human leukocyte genes (HLA-A, HLA-B, HLA-DRB1, and HLA-DQB1), catechol-Omethyltransferase (COMT), opioid receptor Mu 1 (OPRM1), tumour necrosis factor alpha (TNFA), interleukin-6 (IL6), and GTP cyclohydrase (GCH1) that were significantly associated with www.painjournalonline.com 827 Table 1 Characteristics of included studies in the systematic review. The association between A118G (Asn40Asp) in OPRM1 and the risk of developing NP has been investigated in 3 studies.
8,30,41
Cheng et al. 8 examined the association of rs1799971 with 15 painful and 50 painless diabetic foot ulcer patients and reported that patients carrying this variant were less susceptible to NP (OR, 0.24; CI, 0.07-0.80, P 5 3.8 3 10 202 ). By contrast, rs1799971 was not significantly associated with NP in individuals with PPSP (P 5 0.58). 30 Kalliomaki et al. showed no significant differences in the distribution of rs1799971 with NP in 47 Swedish subjects who had undergone hernia surgery compared with pain-free subjects (P 5 0.935). This study was not considered for meta-analysis because allele frequency data were not reported explicitly. 41 The conflicting results might be due to the low number of cases (n , 50) and controls (n , 115) used in these studies. The metaanalysis of 2 studies 8, 30 found that rs1799971 was not significantly associated with NP, with no heterogeneity (OR, 0.55; CI, 0.27-1.11; P 5 0.09) (Fig. 4) .
COMT
COMT encodes catechol-O-methyltransferase and this involved in the breakdown of catecholamine neurotransmitters. 47 Five studies in our review interrogated the association of rs4680 in COMT with different NP conditions and reported inconsistent results. Armero et al. 1 were the first to investigate the association between COMT variant and NP, in Spanish patients with distinct NP conditions. They found no significant distribution of Val158Met genotypes in NP cases compared with healthy controls (P 5 0.9). Similarly, another Spanish cohort of 109 subjects did not show any significant association between COMT and CTS. 20 However, this study reported that CTS Summary of reported statistical methods and outcomes from all included studies and estimated quality score for each study. 21 These conflicting results in the same population may be because they were examining NP of differing aetiology. Another cohort of 258 Norwegian subjects with sciatica did not show an association between rs4680 and NP risk (P 5 0.1). 38 They found a significant association between the Met allele of COMT and pain severity and demonstrated that this may contribute to the progression of NP in sciatica patients. 38 Finally, Hegarty and Shorten 30 found no significant association between COMT and PPSP. The meta-analysis of all 5 studies from the European population with a total of 589 NP patients and 579 controls did not show a significant association between the Met allele of COMT and NP (rs4680, OR, 0.95; CI, 0.81-1.13; P 5 0.584) (Fig. 5) .
SCN9A
SCN9A is involved in ion channel activity. The recent study by Li et al. 44 found that 4 statistically significant variants were associated with 887 PDPN patients compared with 1029 controls (rs7449889; OR, 2.6; P
202 ). Genetic variants in rs4369876 and rs12478318 SNPs in SCN9A were also associated with pain severity. . 10 A significant association of the 5-HTTLPR short-short genotype with TN pain severity was also reported. This study found no association between rs25531 in SCL6A4 and TN risk or pain severity (P , 0.05).
CACNG2
CACNG2 encodes the transmembrane AMPAR regulatory protein (TARP) gamma-2 which modulates neuronal calcium channels. 59 Nissenbaum et al. 53 interrogated the association between 12 polymorphisms in CACNG2 and pain in breast cancer subjects who had undergone breast surgery. A significant association of the A-C-C CACNG2 haplotype (rs4820242-rs2284015-rs2284017; OR, 1.65; P 5 1 3 10-02) with susceptibility to PPSP was reported in this study, although they did not confirm that the pain was specifically neuropathic. Table 2 ). Among these, 3 studies examined HLA frequencies in the independent cohorts of subjects with persistent pain for more 55 were the first to report positive associations of the HLA-alleles, HLA-A*33 and HLA-B*44, and an HLA-DRB1*1302 haplotype with PHN in a Japanese population. Sato et al. 61 confirmed these associations in the same population. Two studies examined these associations in 2 independent Japanese cohorts that included HZ patients with pain and without pain as well as healthy controls. 60, 65 These suggested that the risk alleles contribute to the development of PHN but are not associated with HZ. A Korean study by Chung et al. 9 validated the previously reported HLA risk alleles for PHN and found that HLA-B*44 showed the strongest association with PHN although not with HZ. In addition, this study reported positive associations of HLA-B*13, -B*15, DRB1*10.01, and DRB1*1202 with PHN. Dominguez et al. 17 reported significant associations of HLA-DRB1*04 and HLA-DQB1*03:02 allele frequency and haplotype frequency in patients with persistent pain more than 6 months after surgery, compared with those without persistent pain. Although there are differences in HLA allele typing between the studies, we combined the frequency of allele subtypes and calculated the OR and CI for meta-analysis.
The meta-analysis included all studies that found significant associations of HLA-DRB1*13, HLA-DRB1*04, HLA-A*02, HLA-A*33, HLA-B*44, and HLA-DQB1*03 alleles in 2 subgroups: patients who developed NP after HZ or after surgery compared with patients who did not develop NP after HZ or after surgery and patients who developed NP after HZ compared with healthy controls. The metaanalysis of 4 studies (Figs. 6A,C,E,G) . The HLA-DRB1*13 allele showed a significant association with NP (PHN and PPSP) compared with the subjects with no pain after HZ infection or after inguinal hernia surgery, with no heterogeneity (OR, 1.59; CI, 1.04-2.41; P 5 3.1 3 10 202 ) 9, 17, 60, 65 (Fig. 6B) . The meta-analysis of 2 studies 17, 55 found that NP (PHN and PPSP) was associated with HLA-DQB1*03, with no heterogeneity (OR, 2.86; CI, 1.57-5.21; P 5 6 3 10 204 ) (Fig. 6D) . Meta-analysis of HLA-A*02 alleles from 3 studies 9,60,65 found a significant protective effect on PHN, with no heterogeneity (OR, 0.60; CI, 0.41-0.90; P 5 1 3 10 202 ) (Fig. 6F) and HLA-A*33 increased the risk of developing NP compared with patients who did not develop NP after HZ (OR, 2.32; CI, 1.42-3.80; P 5 8 3 10 204 ) (Fig. 6H) . Meta-analysis found that NP was strongly associated with HLA-B*44 and that this allele increased the risk of developing NP compared with healthy controls as well as HZ patients without PHN (OR, 3.17; CI, 2.22-4.55; P 5 3.5 3 10 210 and OR, 3.50; CI, 2-6.11; P 5 1.8 3 10 205 ), with very low heterogeneity ( Fig. 6I and J) .
Cytokines
Noponen-Hietala et al. investigated the association between 16 sequence variations in 10 proinflammatory cytokine genes (interleukins and tumour necrosis factor) and NP. They found a significant association between rs13306435 (T15A) in IL6 and NP after correcting for multiple testing (rs13306435; OR, 4.4; CI, 1.2-5.7; P 5 1.1 3 10 202 ). The associations between variants in IL1A, IL1B, and TNFA and NP were not statistically significant after multiple correction. 54 Further haplotype analysis using 4 SNPs (rs1800797; G-597A, rs1800796; G-572C, rs1800795; G-174C, and rs13306435; T15A) in IL6 showed a significant association with sciatica, and most notably, the GGGA haplotype was strongly associated with NP (OR, 5.4; CI, 1.5-9.2; P 5 3.3 3 10 203 ). Stephens et al. 64 reported that 13 SNPs in 7 proinflammatory and anti-inflammatory cytokine genes (IFNGR1, IL1B, IL2, IL6, IL8, IL17A, NFKB2, and TNFA) were not significantly associated with NP after adjusting for covariates such as race, pain before surgery, and pain severity after surgery. They found that variants in interleukin-1 receptor 2 (IL1R2) (rs11674595; OR, 36.07; CI, 2.02-643.37; P 5 1 3 10 202 ) and the CGCGATT haplotype in interleukin-10 (IL10) (rs3024505-rs3024496-rs1878672-rs1518111-rs1518110-rs3024491) were significantly associated with NP after adjusting for covariates (OR, 0.21; CI, 0.05-0.91; P 5 3 3 10 202 ). Kalliomaki et al. 41 reported that rs1800629 in TNFA was significantly associated with the risk of developing NP in 47 Swedish subjects who had undergone hernia surgery (relative risk, 1.93; CI, 1.03-3.61; P 5 3.6 3 10
202
). All these studies examined different variants in TNFA and were consistent in reporting associations with NP.
Metabolism
GCH1
Three studies examined the association of genetic variants in GCH1 with the risk of developing NP, in populations with different ancestries. Wadley et al. 75 investigated the association of GCH1 (rs10483639, rs752688, rs4411417, rs8007201, rs3783641, and rs8007267) with NP in HIV-SN subjects of black African ethnicity. They found that a 3-SNP haplotype (CAT) and a 6-SNP haplotype (CTCGAT) were associated with a lower risk of having NP (P 5 2 3 10 202 , and P 5 4 3 10 202 ) but no single SNP showed an association with NP. Kalliomaki et al. 41 found no significant association of the rs8007267-rs3783641-rs10483639 haplotype in GCH1 with NP in 47 Swedish subjects who had undergone hernia surgery. Hegarty and Shorten 30 reported a significant association between the C allele of rs8007267 in GCH1 and PPSP (P 5 2 3 10 202 ) but not with other SNPs (rs3783641, rs10483639). A meta-analysis could not be performed because not all studies provided genotype information.
Iron metabolism-related genes
Kallianpur et al. 40 studied the association between genetic variants in 19 iron-regulatory and iron transport-pathway genes and distal peripheral neuropathic (DPN) pain in 168 HIV-SN subjects from an ad-mixed American population. They found significant associations between DPN and 17 variants in 8 genes encoding: aconitase 1 (ACO1), beta-2-microglobulin (B2M), bone morphogenetic protein 6 (BMP6), frataxin (FXN), ceruloplasmin (CP), transferrin (TF), transferrin cell surface receptor (TFRC), and solute carrier family11 member2 (SLC11A2). Polymorphisms (rs2026739 and rs7033149) at 9p21.1 in ACO1 were associated with increased risk (OR, 1.5; CI, 1.1-2.0; P 5 7 3 10 203 and OR, 1.6; CI, 1.1-2.4; P 5 1.2 3 10 202 ) and rs4495514 in ACO1 was associated with a decreased risk of developing NP in HIV-SN subjects (OR, 0.4; CI, 0.2-0.9; P 5 3.6 3 10 202 ). They reported that rs16966334 and rs1901531 in B2M (OR, 2.4; CI, 1.3-4.2; P 5 3 3 10 203 , and OR, 1.6; CI, 1.1-2.5; P 5 2.8 3 10 202 ) and variants in CP increased the risk of developing NP (rs13072552; OR, 1.6; CI, 1.1-2.4; P 5 7 3 10 203 , rs13075921; OR, 1.6; CI, 1.0-2.4; P 5 4.8 3 10 202 , and rs3816893; OR, 1.9; CI, 1.2-3.0; P 5 4 3 10 203 ). They also found that rs270388, rs267202, and rs267206 in BMP6 were significantly associated with NP (OR, 1.3; CI, 1.0-1.8; P 5 5 3 10 The first published GWAS study on NP performed by Meng et al. reported suggestive significant SNPs (P , 10
26
) at 8p21.3 near GFRA2 (glial cell-line derived neurotrophic factor receptor alpha 2), which is related to the receptor signalling pathway as well as to the immune response. In this study, a total of 572 diabetic patients with NP, defined by their prescription history and a positive monofilament sensory test on the foot, were compared with 2491 diabetic patients without NP in the Scottish populationbased GoDARTS cohort. 49 The most significant intergenic SNP, rs17428041 near GFRA2, showed borderline significance in association with NP (OR, 0.67; CI, 0.57-0.78; P 5 1.77 3 10 27 ).
PRKCA
PRKCA (protein kinase C alpha) encodes for protein kinase C alpha protein and is involved in neurotransmission and apoptosis signalling. Warner et al. found an association between a variant, rs887797, in PRKCA that reached suggestive significance (P 5 4.29 3 10 206 ) and possible NP subjects who had undergone posttotal joint replacement. This finding was validated in 2 independent UK cohorts of individuals who had undergone hip or knee replacement and individuals with knee pain and screened for NP using the painDETECT questionnaire from the Rotterdam study. 77 They conducted a meta-analysis of these cohorts which showed a suggestive association of rs887797 in PRKCA with NP (OR, 2.41; CI, 1.74-3.34; P 5 1.29 3 10 207 ) in the randomeffects recessive model. A sex-specific GWAS reported a suggestively significant intergenic SNP at 8q23.1 mapped to nearby HMGB1P46 and NP in male individuals with diabetes compared with patients without NP in the Scottish population-based GoDARTS cohort (rs6986153; OR, 1.67; CI, 1.34-2.08; P 5 8.02 3 10
27
). 48 Meng et al. 48 also reported a suggestively significant intergenic SNP at 
Discussion
This systematic review has summarized 29 genetic studies in humans that have interrogated the relationship between genetic factors and the presence of different NP conditions. All included studies in this review have defined the NP patients based on clinical examination or clinical assessment or pain questionnaire or prescription history, and controls as either healthy controls or patients without pain at the time of the study. We identified several genetic-associated variants in 28 genes that are involved in various biological pathways including neurotransmission, receptor signalling, immune response, iron metabolism, drug metabolism, receptor binding, and ion binding. The majority of reported variants near genes overlap with enhancer or promoter histone markers, and few genes are transcription factors and targets for microRNAs. This indicates that few of these variants influence protein expression directly, and that most only indirectly influence the expression of genes. It suggests that epigenetic mechanisms may contribute to NP risk. However, the majority of the included studies had small sample sizes and lacked validation. One potential limitation of all included studies in this review was the employment of varying case definitions, and uncertain control ascertainment, irrespective of different NP conditions. Very few studies addressed the exclusion of controls based on comorbidities related to any pain. Moreover, few candidate gene association studies tested the association of variants using a model without multiple adjustments. Most importantly, only a small number of studies have adjusted the association model with either more general covariates such as age, sex, smoking, and BMI or with study-specific covariates such as pain severity, ethnicity, surgery type, and therapy. Some studies had not reported summary statistics in detail. The GWAS in this field are few and have failed to replicate previously reported genes, perhaps because of small sample size or differences in case definition. In future studies, these limitations need to be considered and resolved. Traditional molecular genetics studies found gain-of-function mutations in SCN9A, SCN11A, and Trp101stop mutations in NP patients compared with the healthy controls. SCN9A and SCN11A are mainly expressed in nociceptive sensory neurons of the dorsal roots and play an important role in regulating pain signals. 2, 58 Evidence suggests that the sodium channel genes Na v 1.9 and Na v 1.7 could be used as molecular targets for treating NP. 19 The most significant association between nonsynonymous variant (rs3750904) in SCN9A and NP in diabetic patients has been confirmed in a genetic association study. Moreover, these studies have identified potential candidate genes for future association studies. MPZ was only identified in a single study with a specific NP condition, and conclusions must be limited. To date, 3 GWA studies on different NP conditions (PDPN and PPSP) have identified suggestive signals (P , 5 3 10 206 ) at chr8p21.3, chr1p35.1, chr8p23.1, and chr17q24.2 loci, in discovery cohorts from the European population, and the association of chr17q24.2 (PRKCA) with NP was confirmed in an independent cohort of subjects with knee or hip replacement surgery. Other loci, chr8p21.3, chr1p35.1, and chr8p23.1, associated with NP in a population of diabetic patients, have not been confirmed in replication cohorts, and this may be because of differences in case definition or lack of appropriate sample sizes. Of the CGAS reviewed in this study, variants within SCN9A, IL10, IL1R2, B2M, BMP6, TF, CP, TFRC, ACO1, FXN, SLC6A4, and CACNG2 were only interrogated in single studies and significantly associated with NP but this needs to be validated in larger sample sizes. Genetic variants in COMT, HLA genes, OPRM1, GCH1, IL6, and TNFA were identified to have an association with NP in more than one study.
The most extensively studied candidate variant is A118G in exon 1 of OPRM1 in several pain conditions; this has been found to be associated with lower pain levels and is mainly involved in neurotransmission pathways. This missense variant at 6q25.2 results in an amino acid substitution (Asn40Asp) which may increase the binding affinity of b-endorphin. Meta-analysis of 2 studies found no significant association between rs1799971 in OPRM1 and NP. However, replication cohorts with larger sample sizes are necessary to validate these findings. A systematic review and meta-analysis study has reported that individuals carrying the Met allele of COMT are more susceptible to other types of chronic pain and to severity of pain. 66 Our meta-analysis results found that COMT was not significantly associated with NP; although one study reported a significant association with NP in MS patients, other studies reported nonsignificant associations with sciatica, PHN, and PPSP. Further studies with larger sample size and consistent case and control definitions may reveal the true association of COMT variants with NP.
Evidence suggests that polymorphisms in GCH1 decrease pain levels by altering the expression of this enzyme. 46, 68 One study found a positive association between an intronic variant, rs8007267, in GCH1 and PPSP. Two studies investigated the association of GCH1 haplotypes (rs752688, rs3783641, and rs8007201) with NP and reported inconsistent results. Larger cohort studies might validate the association of rs8007267 with NP, confirm the haplotypes' association, and identify more NP susceptibility variants in GCH1.
The HLA gene complex is a highly polymorphic region located on the short arm of chromosome 6 and comprises more than 200 genes. Association between HLA genes and NP in HZ patients (PHN) are the most studied in the East Asian population and one study investigated this relationship in a European population. Our fixed-effect meta-analyses' result found that polymorphisms in HLA-DRB1*13, HLA-DRB1*04, HLA-DQB1*03, HLA-A*33, and HLA-B*44 showed significant increases in the risk of having NP and effect sizes and direction were consistent across the studies. By contrast, HLA-A*02, a protective allele, conferred reduced risk of NP. Only moderate heterogeneity was observed in HLA-DRB1*04 and HLA-A*02 combined analyses due to different ethnicity. Apart from HLA genes, cytokines such as IL6 and TNFA have been shown to be linked to several chronic pain conditions 42 and variants in TNF haplotypes have been shown to be associated with pain severity in HIV-SN patients of South African ancestry. 31 Interestingly, activation of immune cells and then overexpression of pro-inflammatory cytokines has been seen in NP patients. 3, 71 Our review also found 2 studies that examined the contribution of several variants in inflammatory cytokine genes to the risk of developing NP and found that IL6, IL10, IL1R2, and TNFA were significantly associated with NP but these studies explored different variants in these genes and were limited by study sample size. Therefore, we could not combine these studies to assess their true association with NP susceptibility. However, large-scale studies would reveal the relationship between inflammatory response and its role in the pathophysiology of NP. These studies demonstrate that further investigation of polymorphisms in HLA genes and inflammatory genes could identify potential genetic variants which could be used as drug targets for NP to modulate the immune responses.
Strengths and limitations of this review
To the best of our knowledge, this systematic review is the first to date summarizing the genetic factors that contribute to the risk of developing NP in humans. Recent reviews focussed on the risk factors, including genetic factors, for specific conditions including PDPN and PHN. 22, 27 Strengths of this review include the literature search for articles reporting molecular genetic findings and genetic association studies in 5 databases, applying a standard study design according to PRISMA guidelines, using explicit search terms using previously validated key words, using text mining methods to filter studies based on appropriate inclusion and exclusion criteria, updating recent records using original search strategies, and using data synthesis of all eligible genetic association studies. We used standard meta-analysis study design and reporting methods according to STREGA quality guidelines for genetic association studies.
This review excluded non-English language articles and may therefore have missed any important new findings reported in other languages. Our meta-analyses results were limited by the small sample sizes of relatively few eligible studies and this may affect the robustness of the results. For example, heterogeneity is difficult to estimate when studies are few in number. 24, 32 A few included studies in this review explored the association of SNPs with NP as well as pain severity; this review focussed only on genetic factors for the risk of developing NP and may not have captured NP severity-associated genetic variants. These variants may be involved in NP susceptibility as well, and we may have missed them. Our included studies examined genetic factors associated with NP in studies that reported both human and experimental animal models as well but we have not considered results from animal model studies alone. The translation of animal model studies to human is still under debate, especially in this field. Finally, a few included studies from the same research group may overlap with each other.
Recommendations for future research
Our systematic review highlights the current knowledge of genetic factors that influence the risk of having NP and reveals recommendations for future studies. Our review lists potential candidate genes which can be validated in further studies with large sample sizes from different ethnic groups. In addition, future haplotype analysis could reveal the true association of haplotype blocks in candidate genes with NP susceptibility. A large-scale GWAS with consensus NP phenotype in independent cohorts could shed light on other potential genetic polymorphisms across the genome associated with NP susceptibility or protection. Pathway analysis could explore additional genes involved in the immune response, neurotransmission, and metabolism pathways which would be useful to identify multiple genes in pathways that contribute to NP susceptibility. In addition, exome sequencing might identify common and rare causal variants associated with NP risk.
Conclusions
This systematic review gathered all genetic studies in humans and identified several variants in or near 28 genes significantly associated with NP. Our meta-analysis results suggest that variants in HLA-DRB1*13, HLA-DRB1*04, HLA-DQB1*03, HLA-A*33, and HLA-B*44 increase the risk of developing NP, whereas variants in HLA-A*02 decrease the risk and variants in COMT and OPRM1 were not associated with NP. However, larger cohort studies are necessary to validate these findings, and these could identify biomarkers for clinical prognosis and drug targeting. The limited number of case-control GWAS on NP highlights the need for large-scale GWAS with a consistent case definition. Our review suggests that multiple genetic risk factors from distinct pathways influence NP susceptibility, and their interactions may elucidate the genetic mechanisms underlying NP.
